Clearmind Medicine Inc Reports Promising Results in Pre-Clinical Trial for Combination Therapy

LOS ANGELES- Clearmind Medicine Inc has announced the results of its pre-clinical trial involving a combination therapy, marking a significant step in the development of treatments for addictions, obesity, metabolic disorders, and depression. The trial evaluated the efficacy and safety of combining Clearmind’s proprietary psychedelic treatment, MEAI, with SciSparc Ltd’s Palmitoylethanolamide (PEA), an anti-inflammatory agent.

The Focus of the Pre-Clinical Trial

The primary goal of the trial was to determine the optimal dosage for this combination therapy and to assess its impact on several metabolic and behavioral parameters. These included fat oxidation, locomotor activity, and feeding behavior. The study involved fourteen treatment groups with a total of 84 animals, receiving varying doses of MEAI with a constant dose of PEA.

Positive Outcomes Observed

The trial results were promising. The administration of MEAI showed a high degree of tolerance across all experimental groups, maintaining the animals’ viability. Notably, the combination of MEAI and PEA, especially at dosages of 20 and 10 mg/kg, resulted in increased oxygen consumption and carbon dioxide emission. These findings are indicative of enhanced metabolic processes and fat burning. Additionally, the therapy led to an increase in energy expenditure and fat oxidation.

Impact on Feeding Behavior and Energy Utilization

Clearmind’s combination therapy also affected feeding behavior. Food consumption and meal sizes were reduced, particularly at MEAI doses of 40 and 20 mg/kg, suggesting a potential application in managing obesity and metabolic disorders. The study observed slight increases in carbohydrate oxidation, mainly at doses of 20 and 10 mg/kg.

Changes in Locomotor Activity

While the treatment significantly reduced ambulation at higher doses (40 and 20 mg/kg), it did not adversely affect voluntary activity, indicating a favorable safety profile for the combination therapy.

Corporate Update: Reverse Share Split

In a concurrent announcement, Clearmind Medicine also informed stakeholders of a 1-for-30 reverse share split, effective immediately. This corporate action represents a strategic move by the company, potentially aligning its stock structure with its ambitious clinical and commercial goals.

The pre-clinical trial results from Clearmind Medicine Inc present a compelling case for the combined use of MEAI and PEA in treating a range of conditions, from addictions to metabolic disorders. The favorable safety profile, alongside significant impacts on metabolic processes and feeding behaviors, positions this therapy as a promising candidate for further clinical development. The company’s reverse share split further underscores its commitment to advancing its strategic objectives in the pharmaceutical arena.